# ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion

> **NCT04744051** · PHASE1 · UNKNOWN · sponsor: **American CryoStem Corporation** · enrollment: 20 (estimated)

## Conditions studied

- Post-Concussion Syndrome

## Interventions

- **DRUG:** 50 Adipose Derived Stem Cell Infusion
- **DRUG:** 150 Adipose Derived Stem Cell Infusion
- **DRUG:** 300 Adipose Derived Stem Cell Infusion
- **DRUG:** Placebo Infusion

## Key facts

- **NCT ID:** NCT04744051
- **Lead sponsor:** American CryoStem Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2024-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04744051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04744051, "ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04744051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*